PEDIATRICS Vol. 91 No. 6 June 1993, pp. 1199-1201
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ZANOLLI, M. D.
Right arrow Articles by KROWCHUK, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ZANOLLI, M. D.
Right arrow Articles by KROWCHUK, D. P.

Phenolphthalein-Induced Fixed Drug Eruption: A Cutaneous Complication of Laxative Use in a Child

MICHAEL D. ZANOLLI MD1, JOANNE MCALVANY MD1, and DANIEL P. KROWCHUK MD1

1 Depts of Dermatology and Pediatrics, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC

Drug eruptions are a common dermatologic problem faced by pediatricians. Among the most distinctive of these is the fixed drug eruption, a cutaneous inflammatory reaction manifested by solitary or multiple, well-defined, erythematous macules that may become bullous.1,2 Lesions usually occur within a few hours of ingesting the drug, characteristically recur in the same location with each subsequent dose, and leave residual hyperpigmentation. To illustrate the importance and unique features of this unusual reaction, we report the case of a child who experienced a recurrent fixed drug eruption induced by phenolphthalein-containing, nonprescription laxatives.

CASE REPORT

An 8-year-old African-American girl was brought to the Dermatology Clinic for evaluation of pruritic and occasionally swollen "dark spots" that had been present on her face and arms for months.

Submitted on November 13, 1992
Accepted on February 9, 1993




This article has been cited by other articles:


Home page
 Arch DermatolHome page
R. Zeltser, L. Valle, C. Tanck, M. M. Holyst, C. Ritchlin, and A. A. Gaspari
Clinical, Histological, and Immunophenotypic Characteristics of Injection Site Reactions Associated With Etanercept: A Recombinant Tumor Necrosis Factor {alpha} Receptor: Fc Fusion Protein
Arch Dermatol, July 1, 2001; 137(7): 893 - 899.
[Abstract] [Full Text] [PDF]